Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: A randomized controlled trial

JAMA

Volumn 297, Issue 20, 2007, Pages 2201-2209

  Leslie, Toby ^a,b   Mayan, M Ismail ^a   Hasan, M Anwar ^a   Safi, M Hanif ^a   Klinkenberg, Eveline ^a   Whitty, Christopher J M ^b   Rowland, Mark ^b  

^a Department of Research and Development   (Netherlands)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; ANTIMALARIAL AGENT; CHLORPROGUANIL; CHLORPROGUANIL DAPSONE; CHLORPROGUANIL-DAPSONE; DAPSONE; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST; PROGUANIL; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFGHANISTAN; AGED; ANEMIA; ARTICLE; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMETOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; NAUSEA; OPEN STUDY; PAKISTAN; PALLOR; PARASITE; PLASMODIUM VIVAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; COMPARATIVE STUDY; DRUG COMBINATION; DRUG RESISTANCE; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AFGHANISTAN; AGED; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; CHLOROQUINE; DAPSONE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; PAKISTAN; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 34249741129     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.20.2201     Document Type: Article

References (36)

1. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol. 2006;22:353-358.
2. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64(suppl):97- 106.
3. Guerra CA, Snow RW, Hay SI. Defining the global spatial limits of malaria transmission in 2005. Adv Parasitol. 2006;62:157-179.
4. Baird JK. Chloroquine resistance in vivax malaria. Antimicrob Agents Chemother. 2004;48:4075-4083.
5. World Health Organization. The Use of Rapid Malaria Diagnostic Tests, Second Edition. http://www.wpro.who.int/sites/rdt/documents/PUB_9290612045.htm. Accessed November 25, 2006.
6. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria diagnosis: how can it be achieved? Nat Rev Microbiol. 2006;4(suppl):S7-S20.
7. Connolly MA, Gayer M, Ryan MJ, Salama P, Spiegel P, Heymann DL. Communicable diseases in complex emergencies: impact and challenges. Lancet. 2004;364:1974-1983.
8. Young MD, Burgess RW. Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ. 1959;20:27-36.
9. Pukrittayakamee S, Chantra A, Vanijanonta S, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000;44:1680-1685.
10. Wilairatana P, Silachamroon U, Krudsood S, et al. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg. 1999;61:973-977.
11. Imwong M, Pukrittayakamee S, Looareesuwan S, et al. Association of genetic mutations on Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother. 2001;45:3122-3127.
12. Imwong M, Pukrittayakamee S, Cheng Q, et al. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob Agents Chemother. 2005;49:4393-4395.
13. White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113:1084-1092.
14. Rowland M, Rab MA, Freeman T, Durrani N, Rehman N. Afghan refugees and the temporal and spatial distribution of malaria in Pakistan. Soc Sci Med. 2002;55:2061-2072.
15. Brooker S, Leslie T, Kolaczinski K, et al. Spatial epidemiology of Plasmodium vivax, Afghanistan. Emerg Infect Dis. 2006;12:1600-1602.
16. Kolaczinski J, Graham K, Fahim A, Brooker S, Rowland M. Malaria control in Afghanistan: progress and challenges. Lancet. 2005;365:1506-1512.
17. Lang T, Greenwood B. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis. 2003;3:162-168.
18. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother. 1997;41:2261-2264.
19. Mutabingwa TK, Maxwell CA, Sia IG, et al. A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans R Soc Trop Med Hyg. 2001;95:433-438.
20. Sulo J, Chimpeni P, Hatcher J, et al. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet. 2002;360:1136-1143.
21. Alloueche A, Bailey W, Barton S, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004;363:1843-1848.
22. Mutabingwa T, Nzila A, Mberu E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 2001;358:1218-1223.
23. Bouma MJ, Goris M, Akhtar N, Khan N, Kita E. Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and refugee communities in Pakistan: implications for the use of primaquine in regional malaria control programs. Trans R Soc Trop Med Hyg. 1995;89:62-64.
24. Ali N, Anwar M, Ayyub M, Bhatti FM, Nadeem M, Nadeem A. Frequency of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups of Pakistan. J Coll Physicians Surg Pak. 2005;15:137-141.
25. Durrani N, Leslie T, Rahim S, Graham K, Ahmad F, Rowland M. Efficacy of combination therapy with artesunate & amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan. Trop Med Int Health. 2005;10:521-529.
26. United Nations High Commissioner for Refugees. Top 5 refugee hosting countries, beginning 2006. UNHCR Country Information. http://www.unhcr.org/ country/pak.html. Accessed December 4, 2006.
27. Leslie T, Rab MA, Ahmadzai H, et al. Compliance with 14 day primaquine therapy for radical cure of vivax malaria: a randomised placebo controlled trial comparing supervised and unsupervised treatment. Trans R Soc Trop Med Hyg. 2004;98:168-173.
28. Rowland M, Durrani N. Randomised controlled trials of 5- and 14- days primaquine therapy against relapses of vivax malaria in an afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg. 1999;93:641-643.
29. Figueiredo MS, Pinto BO, Zago MA. Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity. Acta Haematol. 1989;82:144-145.
30. Kolaczinski K, Durrani N, Rahim S, Rowland M. Efficacy of sulphadoxine-pyrimethamine plus artesunate for the treatment of vivax malaria: addressing concerns in areas of falciparum and vivax malaria. Trans R Soc Trop Med Hyg. In press.
31. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19:115-120.
32. Ruwende C, Khoo SC, Snow RW, et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 1995;376:246-249.
33. Curtis J, Maxwell CA, Msuya FH, Mkongewa S, Alloueche A, Warhurst DC. Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. J Infect Dis. 2002;186:1861-1864.
34. Nzila AM, Nduati E, Mberu EK, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorteracting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 2000;181:2023-2028.
35. World Health Organization. Guidelines for treatment of malaria. WHO/HTM/MAL/2006.1108. http://www.who.int/malaria/docs/TreatmentGuidelines2006. pdf. Accessibility verified April 23, 2007.
36. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine- pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother. 2002;46:3947-3953.